US OptionsDetailed Quotes
SKYE241220P5000
- 0.95
- 0.000.00%
15min DelayClose Sep 17 13:18 ET
0.00High0.00Low
0.00Open0.95Pre Close0 Volume20 Open Interest5.00Strike Price0.00Turnover110.70%IV5.37%PremiumDec 20, 2024Expiry Date0.72Intrinsic Value100Multiplier24DDays to Expiry0.23Extrinsic Value100Contract SizeAmericanOptions Type-0.6550Delta0.3051Gamma4.51Leverage Ratio-0.0090Theta-0.0021Rho-2.95Eff Leverage0.0040Vega
SKYE BIOSCIENCE INC Stock Discussion
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience (Nasdaq: SKYE) has commented on Novo Nordisk's Phase 2a top-line data for monlunabant, a small-molecule oral CB1 inverse agonist. The study met its primary endpoint, showing at least 6% placebo-adjusted weight loss at 16 weeks. However, dose-dependent neuropsychiatric side effects were observed.
Skye highlights the advan...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity. Skye Bioscience (Nasdaq: SKYE) has launched a Phase 2 clinical trial, CBeyond™, to evaluate its peripheral CB1 inhibitor, nimacimab, for weight loss in patients with obesity.
The study will assess nimacimab's efficacy as a monotherapy and in combination with a GLP-1 receptor agonist (Wegovy®). Key aspects of the trial include:
- 12...
$SKYE BIOSCIENCE INC (SKYE.US)$ $Boundless Bio (BOLD.US)$
I had been eyeing this off for a while. Tried to buy in Jan at 0.019-0.020 but then left it alone as for whatever reason I wasn't able to buy.
Now I see it's gone from 0.02000 to a whopping 3.15.
Damn you Mr Market, that's ice cold!
whhhyyyyyyyyyy?!?!?!?!?! 😭😭
No comment yet